Trademark: 87763013
Status Date
Monday, September 11, 2023
Filing Date
Friday, January 19, 2018
Published for Opposition
Tuesday, October 20, 2020
Abandoned Date
Monday, September 11, 2023
45 Physician support services in the nature of providing legal consultation in the dispensing of prescription drugs for persons with particular cancers; providing survivorship information in the field of oncology, namely, legal advice regarding survivorship; provide individualized expert legal advice and diagnosis
44 Medical services in the field of oncology, nephrology; dispensing of pharmaceuticals; medical and pharmaceutical consultation; pharmaceutical advice; pharmaceutical compounding services; providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical services, namely, providing personalized drug therapy management programs to cancer patients based on the patient's genetic testing results; genetic testing for medical purposes; genetic testing for cancer diagnosis, treatment and prevention purposes; providing genetic sequencing and consulting services via website designed to provide cancer patients and oncologists with custom tailored information about the range of possible treatments and drug therapies for a particular cancer; providing information to patients and physicians via a website to recommend cancer treatment and drug therapies based on the patient's genetic testing results; providing personalized drug therapy services for cancer patients; drug utilization review dispensing services via a website, namely, identifying cancer drug therapies based on a patient's genetic testing results prior to dispensing medications; developing and managing comprehensive treatment programs involving drug therapy, namely, providing comprehensive medical treatment programs involving drug therapy for the treatment of cancer; physician support services in the nature of providing medical consultation in the dispensing of prescription drugs for persons with particular cancers; providing medical evaluations of patients to determine acceptability for participation in clinical trials; providing healthcare medical counseling, screening, diagnosis, prognosis, treatment, relapse, palliative, integrative medicine, survivorship information, namely, providing comprehensive medical treatment programs involving drug therapy, and other related medical information in the field of oncology; Health care services, namely, providing a database in the field of oncology information and featuring inputting and collection of data and information all for treatment and diagnosis purposes; healthcare consultation in the field of cancer treatment research, namely, advising patients on cancer treatment research studies in which they might participate for purposes of treating their conditions; providing an online searchable database in the fields of oncology, bioinformatics, clinical information technology, genomic data and genomic sequence analysis for personalized diagnosis, treatment and prevention of cancer; molecular profiling for providing comprehensive medical treatment programs involving drug therapy for providing medical treatment; providing RNA expression analysis for medical treatment and diagnosis; providing personalized immunotherapy; Medical services, namely, providing cancer diagnosis; providing standard diagnostics and comprehensive diagnostics, namely, providing standard and comprehensive medical testing for diagnostic purposes; medical services, namely, providing personalized drug screening; providing real-time therapeutic response monitoring for medical treatment and diagnostic purposes; provide individualized expert medical advice and diagnosis in the field of oncology; provide machine learning based medical treatment for cancer patients; providing personalized molecular tumor for each patient, namely, providing medical treatment in the nature of providing personalized molecular tumor for each patient for the treatment of cancer; molecular profiling for oncology treatment purposes; providing RNA expression analysis for oncology treatment purposes; providing standard diagnostics and comprehensive diagnostics, namely, oncology patient diagnostic services for medical treatment purposes; providing personalized drug screening for oncology patients for medical purposes; providing real-time therapeutic response monitoring for oncology patients for medical purposes; providing personalized drug screening for medical treatment and diagnostic purposes; provide machine learning based treatment in the nature of medical treatment and diagnostic purposes for cancer patients
42 Medical, clinical and scientific research in the field of oncology, namely, research relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; scientific and technological services, namely, research services for medical purposes in the field of genetic diagnostic assays and pharmaceuticals research for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information and scientific consulting in the field of genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; conducting early evaluations in the field of new genetic diagnostics assays and pharmaceuticals; development, evaluation and medical and scientific research of genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; laboratory research services relating to genetic diagnostic assays for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals, clinical trials and genetics; technical consulting related to scientific and medical studies in the field of genetic diagnostic assay and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; basic and clinical research in the field of oncology, namely, researching genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; providing medical and scientific research information in the field of genetic diagnostic assays, pharmaceuticals and clinical trials for personalized diagnosis, treatment and prevention of cancer; custom design and development of chemical reagents and multiplex sequencing assays for personalized diagnosis, treatment and prevention of cancer; providing an on-line computer database featuring medical and scientific research information in the field of oncology that allows for input and collection of scientific and research data and information relating to genetic diagnostic assays and pharmaceuticals for diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, data mining and pattern recognition, designing clinical studies, and generating genomic data from patient samples for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data comprising patient specific clinical data and scientific clinical studies relating to genetic diagnostic assays and pharmaceuticals for personalized diagnosis, treatment and prevention of cancer; data collection for research purposes, namely, the collection of mathematical and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to cancer treatments for personalized diagnosis, treatment and prevention of cancer; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies for personalized diagnosis, treatment and prevention of cancer; providing a website featuring technology with a web-based interface where medical professionals can view genetic test results and interpretations of the results by scientists and medical professionals in the field of genomics, and select the appropriate treatment and order the necessary pharmaceutical products; providing personalized molecular tumor for each patient, namely, providing medical research information regarding personalized molecular tumor treatments; providing medical research and scientific research information in the field of oncology via the Internet; development of a personalized ctDNA (circulating tumor DNA) assay; molecular profiling for scientific research purposes; providing RNA expression analysis for scientific research purposes; providing standard diagnostics and comprehensive diagnostics, namely, oncology patient diagnostic services for scientific research purposes; providing personalized drug screening for oncology patients for medical research purposes; providing real-time therapeutic response monitoring for oncology patients for medical research purposes; providing crowdsourcing platform in the nature of providing online non-downloadable software for obtaining information and input into a take or project by enlisting the services of a large number of people; molecular profiling for providing comprehensive medical treatment programs involving drug therapy for providing medical research; providing a database in the field of oncology and featuring inputting and collection of data and information all for treatment and diagnosis purposes, namely, providing a computer database in the field of oncology for treatment and diagnosis purposes featuring technology that allows users to input and collect data and information
The English translation of "NAVIO" in the mark is "SHIP".
Sep 11, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Sep 11, 2023
Abandonment - No Use Statement Filed
Feb 2, 2023
Notice Of Approval Of Extension Request E-Mailed
Jan 31, 2023
Sou Extension 4 Granted
Jan 31, 2023
Sou Extension 4 Filed
Jan 31, 2023
Sou Teas Extension Received
Aug 10, 2022
Notice Of Approval Of Extension Request E-Mailed
Aug 8, 2022
Sou Extension 3 Granted
Aug 8, 2022
Sou Extension 3 Filed
Aug 8, 2022
Sou Teas Extension Received
Feb 11, 2022
Notice Of Approval Of Extension Request E-Mailed
Feb 9, 2022
Sou Extension 2 Granted
Feb 9, 2022
Sou Extension 2 Filed
Feb 9, 2022
Sou Teas Extension Received
Aug 7, 2021
Notice Of Approval Of Extension Request E-Mailed
Aug 5, 2021
Sou Extension 1 Granted
Aug 5, 2021
Sou Extension 1 Filed
Aug 5, 2021
Sou Teas Extension Received
Feb 9, 2021
Noa E-Mailed - Sou Required From Applicant
Dec 30, 2020
Extension Of Time To Oppose Process - Terminated
Nov 13, 2020
Extension Of Time To Oppose Received
Oct 20, 2020
Official Gazette Publication Confirmation E-Mailed
Oct 20, 2020
Published For Opposition
Sep 30, 2020
Notification Of Notice Of Publication E-Mailed
Sep 14, 2020
Exparte Appeal Terminated
Sep 14, 2020
Approved For Pub - Principal Register
Sep 3, 2020
Examiner's Amendment Entered
Sep 3, 2020
Notification Of Examiners Amendment E-Mailed
Sep 3, 2020
Examiners Amendment E-Mailed
Sep 3, 2020
Examiners Amendment -Written
Aug 15, 2020
Teas/Email Correspondence Entered
Aug 15, 2020
Correspondence Received In Law Office
Aug 12, 2020
Teas Request For Reconsideration Received
Aug 12, 2020
Ex Parte Appeal-Instituted
Aug 12, 2020
Jurisdiction Restored To Examining Attorney
Aug 12, 2020
Exparte Appeal Received At Ttab
Feb 18, 2020
Notification Of Final Refusal Emailed
Feb 18, 2020
Final Refusal E-Mailed
Feb 18, 2020
Final Refusal Written
Jan 24, 2020
Suspension Checked - To Attorney For Action
Jun 19, 2019
Report Completed Suspension Check Case Still Suspended
Jun 14, 2019
Assigned To Lie
Nov 29, 2018
Notification Of Letter Of Suspension E-Mailed
Nov 29, 2018
Letter Of Suspension E-Mailed
Nov 29, 2018
Suspension Letter Written
Nov 8, 2018
Teas/Email Correspondence Entered
Nov 7, 2018
Correspondence Received In Law Office
Nov 7, 2018
Teas Response To Office Action Received
May 8, 2018
Notification Of Non-Final Action E-Mailed
May 8, 2018
Non-Final Action E-Mailed
May 8, 2018
Non-Final Action Written
Apr 30, 2018
Assigned To Examiner
Jan 31, 2018
New Application Office Supplied Data Entered
Jan 23, 2018
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
